血管免疫母细胞性T细胞淋巴瘤的遗传学及 治疗研究进展
Advances in Genetic Characterization and Therapeutic Studies of Angioimmunoblastic T-Cell Lymphoma
DOI: 10.12677/acm.2026.1662276, PDF,    科研立项经费支持
作者: 史宏月：山东第二医科大学临床医学院，山东 潍坊；吕 鑫*：临沂市中心医院血液科，山东 临沂
关键词: 血管免疫母细胞性T细胞淋巴瘤；遗传学特征；治疗；Angioimmunoblastic T-Cell Lymphoma； Genetic Features； Therapy
摘要: 血管免疫母细胞性T细胞淋巴瘤(angioimmunoblastic T-cell lymphoma, AITL)是起源于滤泡辅助性T (Follicular helper T, TFH)细胞的侵袭性外周T细胞淋巴瘤(peripheral T-cell lymphoma, PTCL)，病理学和遗传学特征复杂。二代测序的发展进步使更多遗传学标志被发现，包括表观遗传因子突变(TET2, DNMT3A, IDH2)及TCR相关基因突变等，并针对其生物学特征研发了许多新型药物。在此，本文就AITL的分子遗传学特征及治疗进展作进一步的详述。
Abstract: Angioimmunoblastic T-cell lymphoma (AITL) is an aggressive peripheral T-cell lymphoma originating from follicular helper T (TFH) cells with a complex pathology and genetic profile. Developments in next-generation sequencing have led to the discovery of more genetic markers, including mutations in epigenetic factors (TET2, DNMT3A, IDH2) and TCR-associated genes, etc., and the development of many novel drugs targeting their biological features. This article provides further details on the molecular genetic features and therapeutic advances of AITL.
文章引用：史宏月, 吕鑫. 血管免疫母细胞性T细胞淋巴瘤的遗传学及 治疗研究进展[J]. 临床医学进展, 2026, 16(6): 771-780. https://doi.org/10.12677/acm.2026.1662276

参考文献

[1] Dupuis, J., Boye, K., Martin, N., Copie-Bergman, C., Plonquet, A., Fabiani, B., et al. (2006) Expression of CXCL13 by Neoplastic Cells in Angioimmunoblastic T-Cell Lymphoma (AITL): A New Diagnostic Marker Providing Evidence that AITL Derives from Follicular Helper T Cells. The American Journal of Surgical Pathology, 30, 490-494. [Google Scholar] [CrossRef] [PubMed]
[2] Baseggio, L., Traverse-Glehen, A., Berger, F., Ffrench, M., Jallades, L., Morel, D., et al. (2011) CD10 and ICOS Expression by Multiparametric Flow Cytometry in Angioimmunoblastic T-Cell Lymphoma. Modern Pathology, 24, 993-1003. [Google Scholar] [CrossRef] [PubMed]
[3] Bayda, N., Tilloy, V., Chaunavel, A., Bahri, R., Halabi, M.A., Feuillard, J., et al. (2021) Comprehensive Epstein-Barr Virus Transcriptome by RNA-Sequencing in Angioimmunoblastic T Cell Lymphoma (AITL) and Other Lymphomas. Cancers, 13, 610-627. [Google Scholar] [CrossRef] [PubMed]
[4] Zhao, W., Mourah, S., Mounier, N., Leboeuf, C., Daneshpouy, M.E., Legrès, L., et al. (2004) Vascular Endothelial Growth Factor-A Is Expressed Both on Lymphoma Cells and Endothelial Cells in Angioimmunoblastic T-Cell Lymphoma and Related to Lymphoma Progression. Laboratory Investigation, 84, 1512-1519. [Google Scholar] [CrossRef] [PubMed]
[5] Odejide, O., Weigert, O., Lane, A.A., Toscano, D., Lunning, M.A., Kopp, N., et al. (2014) A Targeted Mutational Landscape of Angioimmunoblastic T-Cell Lymphoma. Blood, 123, 1293-1296. [Google Scholar] [CrossRef] [PubMed]
[6] Wang, C., McKeithan, T.W., Gong, Q., Zhang, W., Bouska, A., Rosenwald, A., et al. (2015) IDH2 R172 Mutations Define a Unique Subgroup of Patients with Angioimmunoblastic T-Cell Lymphoma. Blood, 126, 1741-1752. [Google Scholar] [CrossRef] [PubMed]
[7] Zang, S., Li, J., Yang, H., Zeng, H., Han, W., Zhang, J., et al. (2017) Mutations in 5-Methylcytosine Oxidase TET2 and Rhoa Cooperatively Disrupt T Cell Homeostasis. Journal of Clinical Investigation, 127, 2998-3012. [Google Scholar] [CrossRef] [PubMed]
[8] Sakata-Yanagimoto, M., Enami, T., Yoshida, K., Shiraishi, Y., Ishii, R., Miyake, Y., et al. (2014) Somatic RHOA Mutation in Angioimmunoblastic T Cell Lymphoma. Nature Genetics, 46, 171-175. [Google Scholar] [CrossRef] [PubMed]
[9] Que, F., Zhang, L., Wang, T., Xu, M., Li, W. and Zang, S. (2022) RHOA G17V Induces T Follicular Helper Cell Specification and Involves Angioimmunoblastic T-Cell Lymphoma via Upregulating the Expression of PON2 through an NF-κB-Dependent Mechanism. OncoImmunology, 11, Article 2134536. [Google Scholar] [CrossRef] [PubMed]
[10] Lemonnier, F., Cairns, R.A., Inoue, S., Li, W.Y., Dupuy, A., Broutin, S., et al. (2016) The IDH2 R172K Mutation Associated with Angioimmunoblastic T-Cell Lymphoma Produces 2HG in T Cells and Impacts Lymphoid Development. Proceedings of the National Academy of Sciences, 113, 15084-15089. [Google Scholar] [CrossRef] [PubMed]
[11] Leca, J., Lemonnier, F., Meydan, C., Foox, J., El Ghamrasni, S., Mboumba, D., et al. (2023) IDH2 and TET2 Mutations Synergize to Modulate T Follicular Helper Cell Functional Interaction with the AITL Microenvironment. Cancer Cell, 41, 323-339.e10. [Google Scholar] [CrossRef] [PubMed]
[12] Nam, A.S., Dusaj, N., Izzo, F., Murali, R., Myers, R.M., Mouhieddine, T.H., et al. (2022) Single-Cell Multi-Omics of Human Clonal Hematopoiesis Reveals That DNMT3A R882 Mutations Perturb Early Progenitor States through Selective Hypomethylation. Nature Genetics, 54, 1514-1526. [Google Scholar] [CrossRef] [PubMed]
[13] Zheng, J., Wang, Z., Pan, X., Zhang, Z., Li, H., Deng, X., et al. (2023) DNMT3AR882H Accelerates Angioimmunoblastic T-Cell Lymphoma in Mice. Oncogene, 42, 1940-1950. [Google Scholar] [CrossRef] [PubMed]
[14] Lee, G.J., Jun, Y., Jeon, Y.K., Lee, D., Lee, S. and Kim, J. (2022) Mice Transgenic for Human CTLA4-CD28 Fusion Gene Show Proliferation and Transformation of ATLL-Like and AITL-Like T Cells. OncoImmunology, 11, Article 2015170. [Google Scholar] [CrossRef] [PubMed]
[15] Vose, J., Armitage, J., Weisenburger, D., et al. (2008) International Peripheral T-Cell and Natural Killer/T-Cell Lymphoma Study: Pathology Findings and Clinical Outcomes. Journal of Clinical Oncology, 26, 4124-4130. [Google Scholar] [CrossRef] [PubMed]
[16] Horwitz, S., O’Connor, O.A., Pro, B., Trümper, L., Iyer, S., Advani, R., et al. (2022) The ECHELON-2 Trial: 5-Year Results of a Randomized, Phase III Study of Brentuximab Vedotin with Chemotherapy for Cd30-Positive Peripheral T-Cell Lymphoma. Annals of Oncology, 33, 288-298. [Google Scholar] [CrossRef] [PubMed]
[17] Zong, X., Yang, Z., Zhou, J., Jin, Z. and Wu, D. (2024) Clinical Trial: Chidamide Plus CHOP Improve the Survival of Newly Diagnosed Angioimmunoblastic T-Cell Lymphoma. Frontiers in Immunology, 15, Article ID: 1430648. [Google Scholar] [CrossRef] [PubMed]
[18] Kyriakou, C., Canals, C., Goldstone, A., et al. (2008) High-Dose Therapy and Autologous Stem-Cell Transplantation in Angioimmunoblastic Lymphoma: Complete Remission at Transplantation is the Major Determinant of Outcome-Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. Journal of Clinical Oncology, 26, 218-224. [Google Scholar] [CrossRef] 
[19] Kyriakou, C., Canals, C., Finke, J., et al. (2009) Allogeneic Stem Cell Transplantation Is Able to Induce Long-Term Remissions in Angioimmunoblastic T-Cell Lymphoma: A Retrospective Study from the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. Journal of Clinical Oncology, 27, 3951-3958. [Google Scholar] [CrossRef] 
[20] Ruan, J., Moskowitz, A.J., Mehta-Shah, N., Sokol, L., Chen, Z., Kotlov, N., et al. (2023) Multicenter Phase 2 Study of Oral Azacitidine (CC-486) Plus CHOP as Initial Treatment for Peripheral T-Cell Lymphoma. Blood, 141, 2194-2205. [Google Scholar] [CrossRef] [PubMed]
[21] Bachy, E., Camus, V., Thieblemont, C., Sibon, D., Casasnovas, R., Ysebaert, L., et al. (2022) Romidepsin Plus CHOP versus CHOP in Patients with Previously Untreated Peripheral T-Cell Lymphoma: Results of the Ro-Chop Phase III Study (Conducted by Lysa). Journal of Clinical Oncology, 40, 242-251. [Google Scholar] [CrossRef] [PubMed]
[22] Lemonnier, F., Safar, V., Beldi-Ferchiou, A., Cottereau, A., Bachy, E., Cartron, G., et al. (2021) Integrative Analysis of a Phase 2 Trial Combining Lenalidomide with CHOP in Angioimmunoblastic T-Cell Lymphoma. Blood Advances, 5, 539-548. [Google Scholar] [CrossRef] [PubMed]
[23] Richardson, N.C., Kasamon, Y.L., Chen, H., de Claro, R.A., Ye, J., Blumenthal, G.M., et al. (2019) FDA Approval Summary: Brentuximab Vedotin in First-Line Treatment of Peripheral T-Cell Lymphoma. The Oncologist, 24, e180-e187. [Google Scholar] [CrossRef] [PubMed]
[24] Meeuwes, F.O., Brink, M., van der Poel, M.W.M., Kersten, M.J., Wondergem, M., Mutsaers, P.G.N.J., et al. (2022) Impact of Rituximab on Treatment Outcomes of Patients with Angioimmunoblastic T-Cell Lymphoma: A Population-Based Analysis. European Journal of Cancer, 176, 100-109. [Google Scholar] [CrossRef] [PubMed]
[25] Wulf, G.G., Altmann, B., Ziepert, M., D’Amore, F., Held, G., Greil, R., et al. (2021) Alemtuzumab Plus CHOP versus CHOP in Elderly Patients with Peripheral T-Cell Lymphoma: The DSHNHL2006-1B/ACT-2 Trial. Leukemia, 35, 143-155. [Google Scholar] [CrossRef] [PubMed]
[26] Shi, Y., Jia, B., Xu, W., Li, W., Liu, T., Liu, P., et al. (2017) Chidamide in Relapsed or Refractory Peripheral T Cell Lymphoma: A Multicenter Real-World Study in China. Journal of Hematology & Oncology, 10, 69-73. [Google Scholar] [CrossRef] [PubMed]
[27] Rai, S., Kim, W.S., Ando, K., Choi, I., Izutsu, K., Tsukamoto, N., et al. (2023) Oral HDAC Inhibitor Tucidinostat in Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma: Phase IIB Results. Haematologica, 108, 811-821. [Google Scholar] [CrossRef] [PubMed]
[28] Ruan, J., Zain, J., Palmer, B., Jovanovic, B., Mi, X., Swaroop, A., et al. (2023) Multicenter Phase 2 Study of Romidepsin Plus Lenalidomide for Previously Untreated Peripheral T-Cell Lymphoma. Blood Advances, 7, 5771-5779. [Google Scholar] [CrossRef] [PubMed]
[29] Falchi, L., Ma, H., Klein, S., Lue, J.K., Montanari, F., Marchi, E., et al. (2021) Combined Oral 5-Azacytidine and Romidepsin Are Highly Effective in Patients with PTCL: A Multicenter Phase 2 Study. Blood, 137, 2161-2170. [Google Scholar] [CrossRef] [PubMed]
[30] 魏冲, 赵丹青, 张炎, 等. 西达本胺联合阿扎胞苷治疗复发/难治性血管免疫母细胞性T细胞淋巴瘤的前瞻性临床研究[J]. 中国癌症防治杂志, 2023, 15(1): 51-55.
[31] Ding, K., Liu, H., Yang, H., Zhu, H., Ma, J., Peng, H., et al. (2024) A Prospective Phase 2 Study of Combination Epigenetic Therapy against Relapsed/refractory Peripheral T Cell Lymphoma. Med, 5, 1393-1401.E2. [Google Scholar] [CrossRef] [PubMed]
[32] Shi, Y., Wu, J., Wang, Z., Zhang, L., Wang, Z., Zhang, M., et al. (2021) Efficacy and Safety of Geptanolimab (GB226) for Relapsed or Refractory Peripheral T Cell Lymphoma: An Open-Label Phase 2 Study (Gxplore-002). Journal of Hematology & Oncology, 14, 12-24. [Google Scholar] [CrossRef] [PubMed]
[33] Merrill, M.H., Dahi, P.B., Redd, R.A., McDonough, M.M., Chen, Y., DeFilipp, Z., et al. (2023) A Phase 2 Study of Pembrolizumab after Autologous Stem Cell Transplantation in Patients with T-Cell Non-Hodgkin Lymphoma. Blood, 142, 621-628. [Google Scholar] [CrossRef] [PubMed]
[34] 杨琴, 李嘉琦, 耿洪智, 等. PI3K抑制剂联合阿扎胞苷治疗复发/难治血管免疫母细胞性T细胞淋巴瘤5例研究[J]. 中国实用内科杂志, 2024, 44(10): 861-865.
[35] Mehta-Shah, N., Zinzani, P.L., Jacobsen, E.D., Zain, J., Mead, M., Casulo, C., et al. (2024) Duvelisib in Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma: Final Results from the Phase 2 PRIMO Trial. Blood, 144, 3061-3061. [Google Scholar] [CrossRef] 
[36] Horwitz, S.M., Nirmal, A.J., Rahman, J., Xu, R., Drill, E., Galasso, N., et al. (2024) Duvelisib Plus Romidepsin in Relapsed/Refractory T Cell Lymphomas: A Phase 1b/2a Trial. Nature Medicine, 30, 2517-2527. [Google Scholar] [CrossRef] [PubMed]
[37] Song, Y., Li, Z., Wu, H., Jin, J., Zhou, H., Zhou, K., et al. (2023) A Multicenter Phase2 Trial of Linperlisib in Relapsed or Refractory Peripheral T/NK Cell Lymphomas. Blood, 142, 306-306. [Google Scholar] [CrossRef] 
[38] Song, Y., Malpica, L., Cai, Q., Zhao, W., Zhou, K., Wu, J., et al. (2024) Golidocitinib, a Selective JAK1 Tyrosine-Kinase Inhibitor, in Patients with Refractory or Relapsed Peripheral T-Cell Lymphoma (JACKPOT8 Part B): A Single-Arm, Multinational, Phase 2 Study. The Lancet Oncology, 25, 117-125. [Google Scholar] [CrossRef] [PubMed]
[39] Mathew, D., Marmarelis, M.E., Foley, C., Bauml, J.M., Ye, D., Ghinnagow, R., et al. (2024) Combined JAK Inhibition and PD-1 Immunotherapy for Non-Small Cell Lung Cancer Patients. Science, 384, eadf1329. [Google Scholar] [CrossRef] [PubMed]
[40] Nguyen, T.B., Sakata-Yanagimoto, M., Fujisawa, M., Nuhat, S.T., Miyoshi, H., Nannya, Y., et al. (2020) Dasatinib Is an Effective Treatment for Angioimmunoblastic T-Cell Lymphoma. Cancer Research, 80, 1875-1884. [Google Scholar] [CrossRef] [PubMed]
[41] Zinzani, P.L., Izutsu, K., Mehta-Shah, N., Barta, S.K., Ishitsuka, K., Córdoba, R., et al. (2024) Valemetostat for Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma (VALENTINE-PTCL01): A Multicentre, Open-Label, Single-Arm, Phase 2 Study. The Lancet Oncology, 25, 1602-1613. [Google Scholar] [CrossRef] [PubMed]
[42] Hong, H., Chen, Z., Zhang, M., Peng, Z., Shen, J., Shuang, Y., et al. (2025) A Multicenter, Open-Label, Single-Arm, Phase Ib Clinical Trial of HH2853 Treatment in Patients with Relapsed And/or Refractory Peripheral T-Cell Lymphoma. Journal of Hematology & Oncology, 18, 50-61. [Google Scholar] [CrossRef] [PubMed]
[43] Gao, Y., Huang, Y., Zhang, Q., Yang, H., Li, Y., Li, Y., et al. (2025) Liposomal Mitoxantrone Monotherapy in Patients with Relapsed or Refractory Mature T‐Cell and Natural Killer‐Cell Neoplasms: A Phase 2, Multicenter, Open‐Label, Single‐Arm Trial. Cancer, 131, e35672. [Google Scholar] [CrossRef] [PubMed]
[44] 黄慧强, 李志铭, 刘丽宏, 等. 盐酸米托蒽醌脂质体注射液治疗外周T细胞淋巴瘤有效性和安全性的多中心、非干预性、双向性队列真实世界研究(MOMENT) [J]. 白血病·淋巴瘤, 2023, 32(8): 457-464.
[45] Li, Z., SUN, P., Ding, K., Huang, G., Yang, H. and Wang, Y. (2025) Combination of Mitoxantrone Hydrochloride Liposome with Chidamide in Patients with Relapsed or Refractory Peripheral T Cell Lymphoma: Updated Results of the Phase II Study. Blood, 146, 3639-3639. [Google Scholar] [CrossRef] 
[46] 刘红云, 董松, 曾韫璟, 等. 西达本胺维持治疗预防外周T细胞淋巴瘤自体造血干细胞移植术后复发的临床观察[J]. 第三军医大学学报, 2020, 42(17): 1724-1729.
[47] Krug, A., Saidane, A., Martinello, C., Fusil, F., Michels, A., Buchholz, C.J., et al. (2024) In Vivo CAR T Cell Therapy against Angioimmunoblastic T Cell Lymphoma. Journal of Experimental & Clinical Cancer Research, 43, Article No. 262. [Google Scholar] [CrossRef] [PubMed]

为你推荐